Specialising in cancer and supportive care – pathologies associated with cancerology, chemotherapy and radiotherapy complications and opportunistic infections that develop in immunocompromised patients – BioAlliance Pharma conceives and develops innovative drugs mainly for hospital use, some of which target rare or orphan diseases.

Our targeted approaches, in areas where medical needs are insufficiently met, contribute to overcoming drug resistance and improving health and quality of life for patients.

BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation with patients’ needs.